Guerbet, a specialist in contrast products and solutions for medical imaging, reports sales growth of 7.6% to €194.3 million (+8.8% at constant exchange rates) for the first three months of 2024.

Growth remained particularly strong in Asia (+26.8% at constant exchange rates) and the Americas (+20.1% at constant exchange rates), while the EMEA region (-6.2% at constant exchange rates) was temporarily impacted by the reform in the supply of contrast products in France.

Guerbet confirms its annual objectives of sales growth in excess of 8% on a like-for-like and CER basis, as well as a return of the restated EBITDA margin to a level above that of 2021 (14.4%).

Copyright (c) 2024 CercleFinance.com. All rights reserved.